SCHEMBL4306307

SCHEMBL4306307

CC(C)(C)OC(=O)N1CCC(N(Cc2cccc(Cl)c2)c2ccccc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.53
PTPRB P23467 1/20 0.52
PTPN11 Q06124 1/20 0.52
STS P08842 3/20 0.51
JAK2 O60674 1/20 0.51
JAK1 P23458 1/20 0.51
GPR119 Q8TDV5 3/20 0.47
PGR P06401 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TP53 P04637 3/20 0.47
MAPT P10636 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4304134 0.92 KMT2A (0.52) MEN1KMT2ASMN1; SMN2STSJAK2
SCHEMBL4311539 0.91 MEN1 (0.56) MEN1KMT2ASMN1; SMN2PTPRBPTPN11
SCHEMBL4313481 0.91 MEN1 (0.52) MEN1KMT2ASMN1; SMN2PTPRBPTPN11
SCHEMBL4304125 0.90 TP53 (0.50) MEN1KMT2ASMN1; SMN2PTPRBPTPN11
SCHEMBL4318763 0.89 MEN1 (0.53) MEN1KMT2APTPRBPTPN11STS
SCHEMBL4243351 0.88 MEN1 (0.52) MEN1KMT2ASMN1; SMN2STSJAK2
SCHEMBL6443950 0.88 MEN1 (0.52) MEN1KMT2APTPRBPTPN11STS
SCHEMBL4306665 0.87 MEN1 (0.51) MEN1KMT2APTPRBPTPN11STS
SCHEMBL4302400 0.87 MEN1 (0.53) MEN1KMT2APTPRBPTPN11STS
SCHEMBL5969506 0.86 OPRM1 (0.50) MEN1KMT2APGRCYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP claimed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP claimed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO claimed
US-7488741-B2 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB PHARMA, S.A. (BE) 2009-02-10 US disclosed
EP-1693061-A1 Use of 4-aminoderivatives for the preparation of a medicament for treating neurological diseases UCB, S.A. (BE) 2006-08-23 EP disclosed
EP-1556045-B1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB SA (BE) 2006-08-02 EP disclosed
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments UCB, S.A. (BE) 2006-06-15 US disclosed
EP-1556045-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2005-07-27 EP disclosed
WO-2004030668-A1 4-AMINOPIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS UCB, S.A. (BE) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128753-A1 4-Aminopiperidine derivatives, processes for their preparation and their use as medicaments PNMT, HTR5A, HTR4 MEN1 4456/4885KMT2A 1360/4885SMN1; SMN2 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.